• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.

作者信息

Herishanu Yair, Avivi Irit, Levi Shai, Shefer Gabi, Bronstein Yotam, Moshiashvili Miguel Morales, Ziv Tomer, Scarfò Lydia, Perry Chava, Ghia Paolo

机构信息

Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Department of Hematology, and.

出版信息

Blood Adv. 2022 Jan 11;6(1):148-151. doi: 10.1182/bloodadvances.2021005998.

DOI:10.1182/bloodadvances.2021005998
PMID:34614513
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8500836/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec6f/8753196/aa4fe0031e0e/advancesADV2021005998f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec6f/8753196/34d81c69c02a/advancesADV2021005998absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec6f/8753196/aa4fe0031e0e/advancesADV2021005998f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec6f/8753196/34d81c69c02a/advancesADV2021005998absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec6f/8753196/aa4fe0031e0e/advancesADV2021005998f1.jpg

相似文献

1
Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者接种BNT162b2 mRNA新冠疫苗后六个月的抗体持久性
Blood Adv. 2022 Jan 11;6(1):148-151. doi: 10.1182/bloodadvances.2021005998.
2
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.慢性淋巴细胞白血病患者接种mRNA BNT162b2疫苗后针对严重急性呼吸综合征冠状病毒2的T细胞免疫反应：一项前瞻性开放标签临床试验的结果
Haematologica. 2022 Apr 1;107(4):1000-1003. doi: 10.3324/haematol.2021.280300.
3
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.BNT162b2 mRNA COVID-19 疫苗在慢性淋巴细胞白血病患者中的疗效：血清学和细胞研究。
Chemotherapy. 2022;67(2):91-95. doi: 10.1159/000521229. Epub 2021 Dec 6.
4
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对 mRNA 抗 COVID-19 疫苗 BNT162b2 和 mRNA-1273 的体液反应。
Blood Adv. 2022 Jan 11;6(1):207-211. doi: 10.1182/bloodadvances.2021006215.
5
Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.BNT162b2 mRNA COVID-19 疫苗的抗体反应动力学：7 个月随访研究。
Medicina (Kaunas). 2021 Dec 5;57(12):1330. doi: 10.3390/medicina57121330.
6
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
7
Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.6个月后对BNT162b2 mRNA新冠疫苗抗体反应的动态变化
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab173.
8
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b mRNA COVID-19 疫苗在慢性淋巴细胞白血病患者中的安全性和有效性。
Haematologica. 2022 Mar 1;107(3):625-634. doi: 10.3324/haematol.2021.279196.
9
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者接种BNT162b2 mRNA疫苗后的血清学反应。
Leuk Lymphoma. 2022 Feb;63(2):503-505. doi: 10.1080/10428194.2021.1973673. Epub 2021 Nov 2.
10
[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].[BNT162b2 mRNA新冠疫苗接种后免疫性血小板减少症]
Rinsho Ketsueki. 2021;62(11):1639-1642. doi: 10.11406/rinketsu.62.1639.

引用本文的文献

1
Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination.mRNA疫苗接种者中11个月的新冠病毒结合抗体衰减情况及相关因素：对加强疫苗接种的影响
Access Microbiol. 2023 Nov 28;5(11). doi: 10.1099/acmi.0.000678.v3. eCollection 2023.
2
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?慢性淋巴细胞白血病患者中的新冠病毒肺炎：我们了解到了什么？
Acta Haematol. 2024;147(1):60-72. doi: 10.1159/000534540. Epub 2023 Oct 11.
3
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.

本文引用的文献

1
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
2
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
3
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
多中心随机对照试验方案，旨在研究暂时暂停布鲁顿酪氨酸激酶抑制剂治疗以与 SARS-CoV-2 疫苗接种同步进行及其对慢性淋巴细胞白血病患者免疫反应的影响。
BMJ Open. 2023 Sep 28;13(9):e077946. doi: 10.1136/bmjopen-2023-077946.
4
Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9).来自2022年欧洲白血病感染会议（ECIL 9）的血液系统恶性肿瘤、造血干细胞移植和CAR-T治疗患者COVID-19管理建议更新
Leukemia. 2023 Sep;37(9):1933-1938. doi: 10.1038/s41375-023-01938-5. Epub 2023 Jul 17.
5
Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?胃肠道癌患者接种新型冠状病毒疫苗后免疫原性受损：肿瘤类型有影响吗？
J Gastrointest Oncol. 2023 Jun 30;14(3):1218-1234. doi: 10.21037/jgo-22-1065. Epub 2023 Jun 26.
6
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.mRNA 疫苗对抗 SARS-CoV-2：优势与注意事项。
Int J Mol Sci. 2023 Mar 21;24(6):5944. doi: 10.3390/ijms24065944.
7
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.一项关于慢性淋巴细胞白血病继发抗体缺陷患者皮下免疫球蛋白与静脉制剂疗效的回顾性研究。
Curr Oncol. 2022 Dec 25;30(1):274-283. doi: 10.3390/curroncol30010022.
8
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia.2019冠状病毒病疫苗接种反应及其在慢性淋巴细胞白血病患者中的实际应用
Hemasphere. 2022 Dec 20;7(1):e811. doi: 10.1097/HS9.0000000000000811. eCollection 2023 Jan.
9
Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.慢性淋巴细胞白血病患者接种第四剂 BNT162b2 mRNA COVID-19 疫苗后的细胞和体液反应。
Eur J Haematol. 2023 Jan;110(1):99-108. doi: 10.1111/ejh.13878. Epub 2022 Oct 23.
10
Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience.CLL 患者接种 SARS-CoV-2 mRNA 疫苗后诱导中和抗体的单中心经验。
Clin Exp Med. 2023 Aug;23(4):1197-1203. doi: 10.1007/s10238-022-00877-2. Epub 2022 Sep 8.
BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
4
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.新冠病毒mRNA-1273疫苗第二剂接种后6个月的抗体持久性
N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6.
5
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.
6
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.慢性淋巴细胞白血病患者的 COVID-19 严重程度和死亡率：ERIC、欧洲慢性淋巴细胞白血病研究倡议和 CLL 校园的联合研究。
Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
7
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.